Clinically, HCC patients with metabolic syndrome exhibit 40% lower GPX4 expression compared to non-metabolic counterparts (p < 0.001), correlating with reduced overall survival (Sun et al., 2015a). This evidence concerns the gene GPX4 and hepatocellular carcinoma.